vs
Side-by-side financial comparison of Autonomix Medical, Inc. (AMIX) and Lyell Immunopharma, Inc. (LYEL). Click either name above to swap in a different company.
Autonomix Medical, Inc. produced more free cash flow last quarter ($-3.0M vs $-150.8M).
Autonomix Medical, Inc. is a medical technology firm that develops innovative minimally invasive diagnostic and therapeutic devices focused on cardiac electrophysiology applications. Its core offerings target improved detection and treatment of cardiac arrhythmias, serving healthcare providers and patients across North American and European healthcare markets, with a key focus on advancing care for rhythm-related heart conditions.
Lyell Immunopharma, Inc. is a clinical-stage biotechnology company specializing in the research and development of next-generation chimeric antigen receptor (CAR) T cell therapies to treat various solid tumors. It primarily targets oncology patient segments across North America, focusing on addressing unmet medical needs in hard-to-treat cancer types.
AMIX vs LYEL — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $6.0K |
| Net Profit | $-3.3M | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | -45.5% |
| Net Profit YoY | -20.2% | 26.7% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | $6.0K | ||
| Q3 25 | $0 | $15.0K | ||
| Q2 25 | $0 | $8.0K | ||
| Q1 25 | $0 | $7.0K | ||
| Q4 24 | $0 | $11.0K | ||
| Q3 24 | $0 | $34.0K | ||
| Q2 24 | $0 | $13.0K | ||
| Q1 24 | — | $3.0K |
| Q4 25 | $-3.3M | — | ||
| Q3 25 | $-7.5M | $-38.8M | ||
| Q2 25 | $-3.3M | $-42.7M | ||
| Q1 25 | $-3.2M | $-52.2M | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.8M | $-44.6M | ||
| Q2 24 | $-2.7M | $-45.8M | ||
| Q1 24 | — | $-60.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | -248353.3% | ||
| Q2 25 | — | -589250.0% | ||
| Q1 25 | — | -819528.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -148544.1% | ||
| Q2 24 | — | -396369.2% | ||
| Q1 24 | — | -1852500.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | -258973.3% | ||
| Q2 25 | — | -533550.0% | ||
| Q1 25 | — | -745642.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -131126.5% | ||
| Q2 24 | — | -352376.9% | ||
| Q1 24 | — | -2022233.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-2.13 | ||
| Q2 25 | — | $-2.89 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-3.48 | ||
| Q2 24 | — | $-3.59 | ||
| Q1 24 | — | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.9M | $247.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.6M | $248.2M |
| Total Assets | $10.2M | $340.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | $247.2M | ||
| Q3 25 | $7.5M | $319.6M | ||
| Q2 25 | $8.6M | $276.8M | ||
| Q1 25 | $9.1M | $301.2M | ||
| Q4 24 | $11.8M | $370.5M | ||
| Q3 24 | $5.2M | $440.5M | ||
| Q2 24 | $6.8M | $491.1M | ||
| Q1 24 | — | $526.3M |
| Q4 25 | $8.6M | $248.2M | ||
| Q3 25 | $6.4M | $329.1M | ||
| Q2 25 | $7.0M | $298.9M | ||
| Q1 25 | $8.1M | $336.5M | ||
| Q4 24 | $9.7M | $382.8M | ||
| Q3 24 | $3.0M | $530.7M | ||
| Q2 24 | $5.3M | $566.5M | ||
| Q1 24 | — | $603.2M |
| Q4 25 | $10.2M | $340.1M | ||
| Q3 25 | $7.9M | $408.0M | ||
| Q2 25 | $9.0M | $385.5M | ||
| Q1 25 | $9.8M | $429.8M | ||
| Q4 24 | $12.0M | $490.9M | ||
| Q3 24 | $5.4M | $619.2M | ||
| Q2 24 | $7.1M | $654.1M | ||
| Q1 24 | — | $694.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.0M | $-150.0M |
| Free Cash FlowOCF − Capex | $-3.0M | $-150.8M |
| FCF MarginFCF / Revenue | — | -2513400.0% |
| Capex IntensityCapex / Revenue | — | 13000.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-269.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.0M | $-150.0M | ||
| Q3 25 | $-3.8M | $-28.6M | ||
| Q2 25 | $-2.6M | $-34.5M | ||
| Q1 25 | $-2.6M | $-54.7M | ||
| Q4 24 | $-2.3M | $-162.4M | ||
| Q3 24 | $-1.6M | $-35.0M | ||
| Q2 24 | $-1.9M | $-38.1M | ||
| Q1 24 | — | $-42.0M |
| Q4 25 | $-3.0M | $-150.8M | ||
| Q3 25 | — | $-28.6M | ||
| Q2 25 | — | $-34.6M | ||
| Q1 25 | — | $-55.0M | ||
| Q4 24 | $-2.3M | $-162.9M | ||
| Q3 24 | — | $-35.1M | ||
| Q2 24 | $-1.9M | $-38.4M | ||
| Q1 24 | — | $-42.0M |
| Q4 25 | — | -2513400.0% | ||
| Q3 25 | — | -190926.7% | ||
| Q2 25 | — | -432825.0% | ||
| Q1 25 | — | -785485.7% | ||
| Q4 24 | — | -1480527.3% | ||
| Q3 24 | — | -103238.2% | ||
| Q2 24 | — | -295576.9% | ||
| Q1 24 | — | -1401533.3% |
| Q4 25 | — | 13000.0% | ||
| Q3 25 | — | 413.3% | ||
| Q2 25 | — | 2100.0% | ||
| Q1 25 | — | 3514.3% | ||
| Q4 24 | — | 4218.2% | ||
| Q3 24 | — | 173.5% | ||
| Q2 24 | — | 2546.2% | ||
| Q1 24 | — | 1000.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
